In the wake of a pandemic that exposed the fragility of human bodies and healthcare systems alike, researchers at Mount Sinai Health System turned the flood of clinical data into a form of foresight. Using machine learning trained on the first twelve hours of a patient's hospitalization, they built a model capable of predicting which COVID-19 patients would face kidney failure or death — not to replace clinical judgment, but to sharpen it. The work reflects a broader turn in medicine: the belief that patterns hidden in the ordinary data of illness can, if read early enough, change what happens
Mount Sinai Develops ML Model to Predict Dialysis Need, Mortality in COVID-19 Patients
Cobertura Relacionada
Four patients at a Nashville hospital received potassium instead of pain medication during routine joint replacement sur…
BBC News · Aug 21 UK warns vulnerable groups to avoid runny eggs amid salmonella outbreakUK health authorities warn vulnerable populations to avoid undercooked eggs at restaurants due to a rapidly expanding sa…
BBC News · Aug 21 Meghan in talks for Netflix's The Gentlemen as she considers return to actingMeghan is in early talks to return to acting with a role in Netflix's The Gentlemen, marking her first significant actin…
The Pharmaceutical Journal · Aug 21 Survey reveals aesthetic goals driving weight-loss medication use over health concernsA UK survey shows 78% of respondents would consider weight-loss medications for weddings and holidays rather than health…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
Medical ML research on COVID-19 patient outcomes has no direct geopolitical implications; this is a domestic healthcare innovation.
Lente Econômica
Mount Sinai's ML model predicts dialysis need and mortality in COVID-19 patients, enabling earlier interventions and potentially reducing healthcare costs through optimized resource allocation and clinical decision-making.
Patients benefit from earlier clinical interventions, improved monitoring, and better prognostic conversations with providers, potentially reducing mortality and morbidity while lowering out-of-pocket costs through optimized treatment pathways.
Potential regulatory pathways for AI/ML validation in clinical settings; CMS may develop reimbursement codes for predictive analytics; FDA may establish guidelines for clinical decision-support algorithms; healthcare systems may adopt similar models, driving standardization.